{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:20:35Z","timestamp":1772756435239,"version":"3.50.1"},"reference-count":13,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Addict Res"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; To assess the long-term course of the feasibility and safety of orally administered heroin [diacetylmorphine (DAM)] tablets in substitution treatment of severely addicted opioid users. &lt;i&gt;Design:&lt;\/i&gt; Open-label, prospective cohort study with 2 non-randomly assigned treatment arms: DAM tablets only (n = 128) or DAM tablets combined with injected DAM and\/or other opioids (n = 237). The average duration of the observation period was 62 months. Study endpoints were the time to discharge from treatment and the number of serious adverse events. &lt;i&gt;Results:&lt;\/i&gt; Both patient groups had a higher than 70% retention rate after the first 48 months of treatment, with similar long-term retention rates (after 8 years both groups had retention over 50%). The physician-verified rate of serious adverse events was 0.01 events per application year among the exclusively oral substitution group (intention-to-treat analysis) during the last year of observation, and 0.005 events per application year in the other group. &lt;i&gt;Conclusions:&lt;\/i&gt; Because of their feasibility and safety over years, DAM tablets may be a valuable long-term therapeutic alternative.<\/jats:p>","DOI":"10.1159\/000313335","type":"journal-article","created":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T06:56:19Z","timestamp":1272264979000},"page":"131-138","source":"Crossref","is-referenced-by-count":9,"title":["Long-Term Follow-Up of Orally Administered Diacetylmorphine Substitution Treatment"],"prefix":"10.1159","volume":"16","author":[{"given":"Ulrich","family":"Frick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Zullino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manrique","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Wiesbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambros","family":"Uchtenhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2010,4,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1517%2F14656566.5.4.713"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159%2F000081410"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2801%2906529-1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136%2Fbmj.317.7150.13"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0810635"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1192%2Fbjp.bp.106.026112"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136%2Fbmj.327.7410.310"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1360-0443.2008.02334.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2FS0009-9236%2803%2900199-1"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ejps.2008.11.008"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1360-0443.2006.01569.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2125.2008.03286.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1503%2Fcmaj.060729"}],"container-title":["European Addiction Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/313335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/313335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:11:03Z","timestamp":1745435463000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000313335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000313335","archive":["Portico"],"relation":{},"ISSN":["1022-6877","1421-9891"],"issn-type":[{"value":"1022-6877","type":"print"},{"value":"1421-9891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}